Enlivex Therapeutics (ENLV) Competitors $1.10 -0.01 (-0.45%) As of 01/31/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ENLV vs. HLVX, ME, TARA, ACOG, DBVT, ORMP, ALXO, VOR, CTOR, and ADVMShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include HilleVax (HLVX), 23andMe (ME), Protara Therapeutics (TARA), Alpha Cognition (ACOG), DBV Technologies (DBVT), Oramed Pharmaceuticals (ORMP), ALX Oncology (ALXO), Vor Biopharma (VOR), Citius Oncology (CTOR), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. HilleVax 23andMe Protara Therapeutics Alpha Cognition DBV Technologies Oramed Pharmaceuticals ALX Oncology Vor Biopharma Citius Oncology Adverum Biotechnologies Enlivex Therapeutics (NASDAQ:ENLV) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations. Does the MarketBeat Community believe in ENLV or HLVX? Enlivex Therapeutics received 45 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 79.71% of users gave Enlivex Therapeutics an outperform vote while only 58.82% of users gave HilleVax an outperform vote. CompanyUnderperformOutperformEnlivex TherapeuticsOutperform Votes5579.71% Underperform Votes1420.29% HilleVaxOutperform Votes1058.82% Underperform Votes741.18% Do analysts rate ENLV or HLVX? Enlivex Therapeutics currently has a consensus price target of $9.50, indicating a potential upside of 763.64%. HilleVax has a consensus price target of $3.00, indicating a potential upside of 52.28%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33HilleVax 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders have more ownership in ENLV or HLVX? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 71.1% of HilleVax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, ENLV or HLVX? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$29.07M-$0.98-1.12HilleVaxN/AN/A-$123.57M-$3.10-0.64 Is ENLV or HLVX more profitable? HilleVax's return on equity of -67.27% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -67.57% -58.45% HilleVax N/A -67.27%-51.99% Does the media prefer ENLV or HLVX? In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 2 articles in the media. Enlivex Therapeutics' average media sentiment score of 1.44 beat HilleVax's score of 0.43 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Enlivex Therapeutics Positive HilleVax Neutral Which has more volatility & risk, ENLV or HLVX? Enlivex Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, HilleVax has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. SummaryEnlivex Therapeutics beats HilleVax on 10 of the 14 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.74M$6.87B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-1.127.6680.0317.24Price / SalesN/A320.221,259.7283.26Price / CashN/A73.5045.9637.70Price / Book0.685.275.124.70Net Income-$29.07M$136.98M$111.40M$224.47M7 Day Performance-6.78%-0.84%2.30%-0.19%1 Month Performance-5.98%-0.02%3.13%0.57%1 Year Performance-60.00%7.51%24.60%20.35% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.7669 of 5 stars$1.10-0.9%$9.50+763.6%-60.7%$23.74MN/A-1.1270Short Interest ↓Positive NewsGap DownHLVXHilleVax2.4829 of 5 stars$1.90+0.5%$3.00+57.9%-86.1%$94.64MN/A-0.6120Short Interest ↑Gap DownME23andMe1.4799 of 5 stars$3.61flat$9.40+160.4%-78.8%$94.29M$219.64M-0.14770Earnings ReportHigh Trading VolumeTARAProtara Therapeutics3.5321 of 5 stars$4.55-1.7%$22.67+398.2%+92.9%$93.87MN/A-1.6130Short Interest ↓Gap DownACOGAlpha CognitionN/A$5.96+0.2%N/AN/A$92.56MN/A-2.33N/ANews CoverageGap DownDBVTDBV Technologies3.6522 of 5 stars$4.47-5.5%$22.50+403.4%-54.7%$91.94M$15.73M-0.9980Gap UpORMPOramed Pharmaceuticals1.8798 of 5 stars$2.28-1.7%N/A-25.2%$91.91M$1.34M20.7310Short Interest ↓News CoveragePositive NewsALXOALX Oncology3.227 of 5 stars$1.74+6.7%$8.50+388.5%-89.9%$91.77MN/A-0.5840Short Interest ↓VORVor Biopharma2.8599 of 5 stars$1.33-2.2%$11.36+753.9%-38.3%$91.33MN/A-0.81140Gap DownCTORCitius OncologyN/A$1.27-3.8%$3.00+136.2%N/A$90.87MN/A0.00N/ANews CoveragePositive NewsADVMAdverum Biotechnologies3.9057 of 5 stars$4.33+0.9%$27.83+542.8%-59.8%$90.06M$3.60M-0.72190News CoveragePositive News Related Companies and Tools Related Companies HLVX Competitors ME Competitors TARA Competitors ACOG Competitors DBVT Competitors ORMP Competitors ALXO Competitors VOR Competitors CTOR Competitors ADVM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENLV) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
